Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors
Patients in the placebo group were unable to receive an angiotensin-converting enzyme inhibitor
during the study.
Hypotensive reactions associated with platelet transfusions and angiotensin-converting enzyme inhibitors
Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor
treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass.
An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibitors
from the venom of Bothrops jararaca: isolation, elucidation of structure and synthesis.
The two trials will compare standard therapy using an angiotensin-converting enzyme inhibitor
(ACE-inhibitor) to intensive therapy using both an ACE-inhibitor and an angiotensin receptor blocker (ARB).
The UP-induced activation of ERK1/2 and p38 was attenuated by captopril, an angiotensin-converting enzyme inhibitor
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor
therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
2% of residents with congestive heart failure were not receiving an angiotensin-converting enzyme inhibitor
Juan Leon, from the same laboratory (NWU), showed that captopril, an antifibrotic angiotensin-converting enzyme inhibitor
, is effective in ameliorating experimental autoimmune myocarditis and experimental Chagas heart disease.
Is optimal angiotensin-converting enzyme inhibitor
dosing neglected in elderly patients with heart failure?
This patient now receives an angiotensin-converting enzyme inhibitor
, and his blood pressure readings are consistently normal.
The objective of the study is to evaluate efficacy and safety of two different doses of Nefecon in the treatment of patients with primary IgA nephropathy at risk of developing end-stage renal disease (ESRD), under standardized rigorous blood pressure control with an angiotensin-converting enzyme inhibitor
(ACEI) and/or angiotensin II receptor I blocker (ARB).
The aim of this study was to elucidate the combined effect of the clinically used vitamin K(2) (VK) and angiotensin-converting enzyme inhibitor
(ACE-I) on cumulative recurrence after curative treatment on a total of 87 patients, especially in consideration of neovascularization.